ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca will pay Scorpion Therapeutics $75 million in a deal to develop small-molecule oncology drugs that target transcription factors, proteins that control gene expression. Transcription factors have long been considered targets for cancer treatments but were considered undruggable using conventional approaches. Scorpion was launched in 2020 by chemist Gary Glick and others. It has raised $270 million in two financing rounds.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter